Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Taxol 100mg/16.7ml solution for infusion vials
0801050V0BBABAB
|
Taxol | Paclitaxel | Malignant Disease and Immunosuppression | No data available |
|
Taxol 150mg/25ml solution for infusion vials
0801050V0BBADAC
|
Taxol | Paclitaxel | Malignant Disease and Immunosuppression | No data available |
|
Taxol 300mg/50ml solution for infusion vials
0801050V0BBACAD
|
Taxol | Paclitaxel | Malignant Disease and Immunosuppression | No data available |
|
Taxol 30mg/5ml solution for infusion vials
0801050V0BBAAAA
|
Taxol | Paclitaxel | Malignant Disease and Immunosuppression | No data available |
|
Taxotere 160mg/8ml concentrate for inf vials
0801050D0BBAEAI
|
Taxotere | Docetaxel | Malignant Disease and Immunosuppression | No data available |
|
Taxotere 20mg/0.5ml solution for infusion vials and diluent
0801050D0BBAAAA
|
Taxotere | Docetaxel | Malignant Disease and Immunosuppression | No data available |
|
Taxotere 20mg/1ml concentrate for inf vials
0801050D0BBACAC
|
Taxotere | Docetaxel | Malignant Disease and Immunosuppression | No data available |
|
Taxotere 80mg/2ml solution for infusion vials and diluent
0801050D0BBABAB
|
Taxotere | Docetaxel | Malignant Disease and Immunosuppression | No data available |
|
Taxotere 80mg/4ml concentrate for inf vials
0801050D0BBADAD
|
Taxotere | Docetaxel | Malignant Disease and Immunosuppression | No data available |
|
Tecfidera 240mg gastro-resistant capsules
0802040AKBBABAB
|
Tecfidera | Dimethyl fumar | Malignant Disease and Immunosuppression | No data available |
|
Tegafur 100mg / Uracil 224mg capsules
0801030S0AAABAB
|
Tegafur | Tegafur | Malignant Disease and Immunosuppression | No data available |
|
Temodal 100mg capsules
0801050Y0BBAAAA
|
Temodal | Temozolomide | Malignant Disease and Immunosuppression | No data available |
|
Temodal 140mg capsules
0801050Y0BBAEAE
|
Temodal | Temozolomide | Malignant Disease and Immunosuppression | No data available |
|
Temodal 180mg capsules
0801050Y0BBAFAF
|
Temodal | Temozolomide | Malignant Disease and Immunosuppression | No data available |
|
Temodal 20mg capsules
0801050Y0BBADAD
|
Temodal | Temozolomide | Malignant Disease and Immunosuppression | No data available |
|
Temodal 250mg capsules
0801050Y0BBABAB
|
Temodal | Temozolomide | Malignant Disease and Immunosuppression | No data available |
|
Temodal 5mg capsules
0801050Y0BBACAC
|
Temodal | Temozolomide | Malignant Disease and Immunosuppression | No data available |
|
Temomedac 100mg capsules
0801050Y0BCACAA
|
Temomedac | Temozolomide | Malignant Disease and Immunosuppression | No data available |
|
Temomedac 140mg capsules
0801050Y0BCADAE
|
Temomedac | Temozolomide | Malignant Disease and Immunosuppression | No data available |
|
Temomedac 180mg capsules
0801050Y0BCAEAF
|
Temomedac | Temozolomide | Malignant Disease and Immunosuppression | No data available |
|
Temomedac 20mg capsules
0801050Y0BCABAD
|
Temomedac | Temozolomide | Malignant Disease and Immunosuppression | No data available |
|
Temomedac 250mg capsules
0801050Y0BCAFAB
|
Temomedac | Temozolomide | Malignant Disease and Immunosuppression | No data available |
|
Temomedac 5mg capsules
0801050Y0BCAAAC
|
Temomedac | Temozolomide | Malignant Disease and Immunosuppression | No data available |
|
Temoporfin 1mg/1ml solution for injection vials
0801050AKAAABAB
|
Temoporfin | Temoporfin | Malignant Disease and Immunosuppression | No data available |
|
Temoporfin 20mg/5ml solution for injection vials
0801050AKAAAAAA
|
Temoporfin | Temoporfin | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.